Modality
ADC
MOA
BCL-2i
Target
GPRC5D
Pathway
RNA Splicing
NMOSDACCNASH
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ Oct 2031
Phase 1Current
NCT04586726
850 pts·NASH
2023-05→2031-10·Completed
850 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-115.5y awayInterim· NASH
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
Catalysts
Interim
2031-10-11 · 5.5y away
NASH
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04586726 | Phase 1 | NASH | Completed | 850 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Rimaosocimab | Amgen | Preclinical | FXIa |